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[11C]NNC 12-0722 or [18F]GBR 13119: 
Just What Is "Better"? 
Dear Sir, 
In their recent paper Muller et al. [1] have presented a 
very preliminary evaluation of a potential new PET ra- 
dioligand for the dopamine transporter, [llC]NNC 12- 
0722. This is a compound derived from the better known 
ligands for that site, GBR 12935 and GBR 12909. In 
their paper, the authors discuss previous efforts to utilize 
a fluorine-18 analog of these compounds, namely 
[18F]GBR 13119 (which is fluoroGBR 12935, or desflu- 
oroGBR 12909), and they state "...brain uptake was ge- 
neral and there was no marked accumulation of radioac- 
tivity in regions known to have a high density of dopa- 
mine transporters" (authors' own words). This statement 
is grossly erroneous. 
We had done extensive evaluation of [18F]GBR 
13119, and the closely related compound [~SF]GBR 
12909, including studies in rodents, monkeys and man. 
The monkey PET image published by us (and referenced 
by the authors) clearly shows bilateral accumulation of 
the radiotracer, [18F]GBR 13119, in the striatum of the 
monkey brain [2]. That paper also presents the pharma- 
cokinetic time course for radioactivity in striatum and 
cerebellum, clearly showing a differential accumulation 
in the DA transporter-rich striatal tissue. The striatum to 
cerebellum ratios in monkeys were 1.5-1.7, not that dis- 
similar than what had been previously reported in mon- 
keys for [l~C]nomifensine, a radioligand also successful- 
ly used for primate and human PET imaging of DA 
transporters. Our publications have documented the 
pharmacological specificity of the regional in vivo bin- 
ding of this radiotracer in mammalian brain [2, 3]. Final- 
ly, we have already reported human imaging and full 
pharmacokinetic modelling of [18F]GBR 12909 in hu- 
man brain [4]. 
Certainly some more recent radioligands, such as 
[I1c]CIT, are better imaging agents but their quantitative 
value is still being studied. [HC]NNC 12-0722 might  al- 
so be a better radioligand, but the authors need to do 
much work to prove this point. They have not demon- 
strated in any animal that the in vivo uptake and concen- 
tration of radioactivity in the striatum of an animal can 
be selectively blocked with known, structurally unrela- 
ted antagonists of the DA transporter. They have not de- 
monstrated that the in vivo brain distribution cannot be 
altered by pharmacological treatments with ligands for 
other receptors or transporters. They have not demon- 
strated that the uptake in brain is not due to metabolites, 
which may or may not be binding to the DA transporter. 
At least all of these things have been done for [18F]GBR 
13119 and [18F]GBR 12909, even if they are not "opti- 
mal" imaging agents. 
A full evaluation of [llC]NNC 12-0722 is needed and 
should be pursued. The high brain uptake, and possibly 
more rapid kinetics, are indeed encouraging. Until these 
further studies are complete, [llC]NNC 12-0722 is just 
one of a long list of radioactive compounds, of several 
pharmacological classes, that will concentrate in the 
striatum. 
Michael R. Kilbourn 
Professor of Internal Medicine 
University of Michigan, Ann Arbor, MI 48109, USA 
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We think that it is of principle importance to examine 
the potential of aryl 1,4-dialkylpiperazines as radioli- 
gands for PET imaging. The selectivity of the piperazi- 
nes may be an advantage as compared to the cocaine 
congener fl-CIT. The striatum to cerebellum ratio of 
[18F]GBR 13119 binding in the monkey brain has been 
reported to be 1.51 [1]. Whether this striatal uptake 
should be regarded as marked or not is a semantic issue. 
It is clearly lower than that obtained for [llc]~ -CIT [2] 
or [HC]fl-CFT, which at present are the most widely 
used ligands for PET imaging of the dopamine transport- 
el'. Despite thorough characterization in the rat brain in 
vivo and in vitro, the specificity of [JSF]GBR 13119 bind- 
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